Added to YB: 2025-09-19
Pitch date: 2025-09-18
NVO [bullish]
Novo Nordisk A/S
-18.59%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 394.50
Price Target
70.00 (-78%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
Actionable Stock Set-up 8: Novo Nordisk (NVO)
NVO: Down 60% from highs but dominant in vast diabetes (589M→850M patients by 2050) & obesity (1.7B overweight) markets. 52% GLP-1 share, 57% obesity share. CagriSema pipeline drug shows 11.8% weight loss vs 2.3% placebo. New CEO restructuring, cutting 9K roles for DKK8B savings. Trades at historically low 14x PE despite 18% revenue growth.
Read full article (10 min)